Free Trial

DBV Technologies (DBVT) Competitors

DBV Technologies logo
$0.59 +0.03 (+5.36%)
(As of 11/15/2024 ET)

DBVT vs. KOD, INZY, EDIT, LFCR, CMPX, TSVT, CRBU, OPT, ATAI, and ATYR

Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Kodiak Sciences (KOD), Inozyme Pharma (INZY), Editas Medicine (EDIT), Lifecore Biomedical (LFCR), Compass Therapeutics (CMPX), 2seventy bio (TSVT), Caribou Biosciences (CRBU), Opthea (OPT), Atai Life Sciences (ATAI), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry.

DBV Technologies vs.

Kodiak Sciences (NASDAQ:KOD) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.

Kodiak Sciences has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 1.9% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DBV Technologies has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$260.49M-$3.76-1.47
DBV Technologies$15.73M3.62-$72.73M-$0.90-0.66

In the previous week, Kodiak Sciences had 3 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for Kodiak Sciences and 7 mentions for DBV Technologies. Kodiak Sciences' average media sentiment score of 0.31 beat DBV Technologies' score of 0.04 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DBV Technologies
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kodiak Sciences currently has a consensus price target of $3.50, indicating a potential downside of 36.71%. DBV Technologies has a consensus price target of $6.00, indicating a potential upside of 917.29%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts clearly believe DBV Technologies is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
2 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
DBV Technologies
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kodiak Sciences has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. Kodiak Sciences' return on equity of -77.23% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -77.23% -42.44%
DBV Technologies -815.73%-106.07%-76.17%

DBV Technologies received 385 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 55.51% of users gave DBV Technologies an outperform vote while only 26.47% of users gave Kodiak Sciences an outperform vote.

CompanyUnderperformOutperform
Kodiak SciencesOutperform Votes
18
26.47%
Underperform Votes
50
73.53%
DBV TechnologiesOutperform Votes
403
55.51%
Underperform Votes
323
44.49%

Summary

DBV Technologies beats Kodiak Sciences on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$56.92M$2.91B$5.07B$8.66B
Dividend YieldN/A1.79%5.10%4.06%
P/E Ratio-0.6643.08101.9217.46
Price / Sales3.62217.681,196.9569.07
Price / CashN/A178.0141.0436.36
Price / Book1.054.096.345.87
Net Income-$72.73M-$42.42M$119.64M$225.66M
7 Day Performance-12.62%-10.63%-5.13%-1.34%
1 Month Performance-19.21%-5.81%-2.72%1.15%
1 Year Performance-66.10%24.19%31.10%24.02%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DBVT
DBV Technologies
2.8874 of 5 stars
$0.59
+5.4%
$6.00
+917.3%
-65.5%$56.92M$15.73M-0.66106Analyst Forecast
Stock Split
Short Interest ↑
Gap Up
KOD
Kodiak Sciences
3.2747 of 5 stars
$4.92
+2.3%
N/A+188.0%$258.89MN/A-1.3190Analyst Forecast
News Coverage
INZY
Inozyme Pharma
1.8318 of 5 stars
$4.02
-2.0%
N/A-3.0%$258.25MN/A-2.5850
EDIT
Editas Medicine
4.6327 of 5 stars
$3.12
-1.6%
N/A-69.7%$257.55M$61.76M-1.22230Short Interest ↓
LFCR
Lifecore Biomedical
2.7081 of 5 stars
$6.74
+5.5%
N/A-13.9%$248.23M$128.26M84.25690
CMPX
Compass Therapeutics
3.4565 of 5 stars
$1.80
-2.2%
N/A-8.0%$247.66MN/A-4.8620Earnings Report
Analyst Downgrade
Short Interest ↓
Analyst Revision
News Coverage
Gap Up
TSVT
2seventy bio
2.4915 of 5 stars
$4.73
-5.6%
N/A+66.4%$243.60M$100.39M-1.54440News Coverage
CRBU
Caribou Biosciences
2.9838 of 5 stars
$2.68
-3.6%
N/A-57.9%$242.17M$34.48M-1.62100Analyst Forecast
Short Interest ↓
News Coverage
OPT
Opthea
2.3603 of 5 stars
$4.11
+1.7%
N/A+72.3%$240.00M$124,666.000.008News Coverage
ATAI
Atai Life Sciences
2.4707 of 5 stars
$1.41
+4.4%
N/A+45.0%$236.60M$310,000.00-3.5283News Coverage
Gap Up
High Trading Volume
ATYR
Atyr PHARMA
2.996 of 5 stars
$3.12
+0.6%
N/AN/A$236.50M$350,000.00-3.3256Short Interest ↑
News Coverage

Related Companies and Tools


This page (NASDAQ:DBVT) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners